NCT00639496View on ClinicalTrials.gov

Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)

PHASE3CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

July 31, 2003

Study Completion Date

July 31, 2003

Conditions
Pulmonary Fibrosis
Interventions
DRUG

n-acetylcysteine

600 mg x 3, for 12 months

DRUG

placebo

Placebo

Trial Locations (7)

41013

Hospital Universitario Virgen del Rocío, Seville

52100

U.O. di Pneumologia-Ospedale, Arezzo

81377

Klinikum Grosshadern, Munich

B- 9000

U.Z. Ghent, Ghent

F 59037

Hôpital A. Calmette, Lille

3435 CM

Stichting St. Antonius Ziekenhuis, Nieuwegein

EH8 9AG

The University of Edinburgh-Medical School, Edinburgh

All Listed Sponsors
lead

Zambon SpA

INDUSTRY

NCT00639496 - Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter